Terms: = Ovarian cancer AND BCL7A, BCL7, 605, ENSG00000110987 AND Treatment
13 results:
1. Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer.
Lai SP; Wang SY; Chan AL; Leung JH; Yip HT
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):541-549. PubMed ID: 38372034
[TBL] [Abstract] [Full Text] [Related]
2. The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis.
Xu K; Wang T; Pan S; He J
Expert Rev Clin Pharmacol; 2023; 16(11):1141-1152. PubMed ID: 37771164
[TBL] [Abstract] [Full Text] [Related]
3. Differences in Stage of cancer at Diagnosis, treatment, and Survival by Race and Ethnicity Among Leading cancer Types.
Zhang C; Zhang C; Wang Q; Li Z; Lin J; Wang H
JAMA Netw Open; 2020 Apr; 3(4):e202950. PubMed ID: 32267515
[TBL] [Abstract] [Full Text] [Related]
4. The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study.
Li L; Ma S; Wu M; Tan X; Zhong S; Lang J
BMJ Support Palliat Care; 2019 Dec; 9(4):373-380. PubMed ID: 31467066
[TBL] [Abstract] [Full Text] [Related]
5. Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer.
Kelemen LE; Warren GW; Koziak JM; Köbel M; Steed H
Gynecol Oncol; 2016 Jan; 140(1):124-30. PubMed ID: 26549109
[TBL] [Abstract] [Full Text] [Related]
6. Definitive Radiation Therapy for Stage I-II Endometrial cancer: An Observational Study of Nonoperative Management.
Yoo S; Hegarty SE; Mishra MV; Patel N; Cantrell LA; Showalter TN
Am J Clin Oncol; 2017 Dec; 40(6):582-589. PubMed ID: 26083557
[TBL] [Abstract] [Full Text] [Related]
7. Risk of premature menopause after treatment for Hodgkin's lymphoma.
Swerdlow AJ; Cooke R; Bates A; Cunningham D; Falk SJ; Gilson D; Hancock BW; Harris SJ; Horwich A; Hoskin PJ; Linch DC; Lister A; Lucraft HH; Radford J; Stevens AM; Syndikus I; Williams MV;
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25139687
[TBL] [Abstract] [Full Text] [Related]
8. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
Aghajanian C; Goff B; Nycum LR; Wang Y; Husain A; Blank S
Gynecol Oncol; 2014 Apr; 133(1):105-10. PubMed ID: 24508841
[TBL] [Abstract] [Full Text] [Related]
9. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
[TBL] [Abstract] [Full Text] [Related]
10. The androgen receptor gene mutations database: 2012 update.
Gottlieb B; Beitel LK; Nadarajah A; Paliouras M; Trifiro M
Hum Mutat; 2012 May; 33(5):887-94. PubMed ID: 22334387
[TBL] [Abstract] [Full Text] [Related]
11. CHFR gene is neither mutated nor hypermethylated in ovarian cancer.
Ludwig AH; Bujko M; Bidzinski M; Kupryjańczyk J
Cancer Detect Prev; 2007; 31(3):257-61. PubMed ID: 17673375
[TBL] [Abstract] [Full Text] [Related]
12. Brain metastases from epithelial ovarian cancer.
Tay SK; Rajesh H
Int J Gynecol Cancer; 2005; 15(5):824-9. PubMed ID: 16174231
[TBL] [Abstract] [Full Text] [Related]
13. Melphalan may be a more potent leukemogen than cyclophosphamide.
Greene MH; Harris EL; Gershenson DM; Malkasian GD; Melton LJ; Dembo AJ; Bennett JM; Moloney WC; Boice JD
Ann Intern Med; 1986 Sep; 105(3):360-7. PubMed ID: 3740675
[TBL] [Abstract] [Full Text] [Related]
